Real-world cost-effectiveness of rivaroxaban and apixaban vs VKA in stroke prevention in non-valvular atrial fibrillation in the UK.

Bowrin, Kevin; Briere, Jean-Baptiste; Levy, Pierre; Millier, Aurélie; Tardu, Jean; Toumi, Mondher.

Afiliação

Bowrin K; Bayer Plc, Reading, UK.
Briere JB; Bayer AG, Berlin, Germany.
Levy P; Université Paris-Dauphine, PSL Research University, LEDa-LEGOS, Paris, France.
Millier A; Creativ-Ceutical, Paris, France.
Tardu J; Creativ-Ceutical, Paris, France.
Toumi M; Aix-Marseille University, Marseille, France.

J Mark Access Health Policy ; 8(1): 1782164, 2020 Jun 25.

Article em En | MEDLINE | ID: mdl-32944199